261 related articles for article (PubMed ID: 21282338)
21. Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells.
Zhang T; Sentman CL
J Immunol; 2013 Mar; 190(5):2455-63. PubMed ID: 23355740
[TBL] [Abstract][Full Text] [Related]
22. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
[TBL] [Abstract][Full Text] [Related]
23. Activated NK cells reprogram MDSCs via NKG2D-NKG2DL and IFN-γ to modulate antitumor T-cell response after cryo-thermal therapy.
Peng P; Lou Y; Wang S; Wang J; Zhang Z; Du P; Zheng J; Liu P; Xu LX
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36521929
[TBL] [Abstract][Full Text] [Related]
24. T cells gene-engineered with DAP12 mediate effector function in an NKG2D-dependent and major histocompatibility complex-independent manner.
Teng MW; Kershaw MH; Hayakawa Y; Cerutti L; Jane SM; Darcy PK; Smyth MJ
J Biol Chem; 2005 Nov; 280(46):38235-41. PubMed ID: 16169855
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.
Sentman ML; Murad JM; Cook WJ; Wu MR; Reder J; Baumeister SH; Dranoff G; Fanger MW; Sentman CL
J Immunol; 2016 Dec; 197(12):4674-4685. PubMed ID: 27849169
[TBL] [Abstract][Full Text] [Related]
26. NKG2D Immunoligand rG7S-MICA Enhances NK Cell-mediated Immunosurveillance in Colorectal Carcinoma.
Wang T; Sun F; Wang Y; Jiang J; Pan M; Yuan M; Zhang H; Du X; Hezam K; Song K; Wang M; Zhang J
J Immunother; 2018 Apr; 41(3):109-117. PubMed ID: 29528990
[TBL] [Abstract][Full Text] [Related]
27. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy.
Zhang T; Lemoi BA; Sentman CL
Blood; 2005 Sep; 106(5):1544-51. PubMed ID: 15890688
[TBL] [Abstract][Full Text] [Related]
28. Cancer immunotherapy using NKG2D and DNAM-1 systems.
Morisaki T; Onishi H; Katano M
Anticancer Res; 2012 Jun; 32(6):2241-7. PubMed ID: 22641658
[TBL] [Abstract][Full Text] [Related]
29. Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy.
Ding H; Yang X; Wei Y
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316666
[TBL] [Abstract][Full Text] [Related]
30. Treatment with a fusion protein of the extracellular domains of NKG2D to IL-15 retards colon cancer growth in mice.
Xia Y; Chen B; Shao X; Xiao W; Qian L; Ding Y; Ji M; Gong W
J Immunother; 2014 Jun; 37(5):257-66. PubMed ID: 24810637
[TBL] [Abstract][Full Text] [Related]
31. Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.
Hornig N; Reinhardt K; Kermer V; Kontermann RE; Müller D
Cancer Immunol Immunother; 2013 Aug; 62(8):1369-80. PubMed ID: 23715927
[TBL] [Abstract][Full Text] [Related]
32. An Fc-optimized NKG2D-immunoglobulin G fusion protein for induction of natural killer cell reactivity against leukemia.
Steinbacher J; Baltz-Ghahremanpour K; Schmiedel BJ; Steinle A; Jung G; Kübler A; André MC; Grosse-Hovest L; Salih HR
Int J Cancer; 2015 Mar; 136(5):1073-84. PubMed ID: 25046567
[TBL] [Abstract][Full Text] [Related]
33. Purinergic targeting enhances immunotherapy of CD73
Wang J; Lupo KB; Chambers AM; Matosevic S
J Immunother Cancer; 2018 Dec; 6(1):136. PubMed ID: 30514403
[TBL] [Abstract][Full Text] [Related]
34. Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF.
Spear P; Barber A; Rynda-Apple A; Sentman CL
J Immunol; 2012 Jun; 188(12):6389-98. PubMed ID: 22586039
[TBL] [Abstract][Full Text] [Related]
35. Targeting NKG2DL with Bispecific NKG2D-CD16 and NKG2D-CD3 Fusion Proteins on Triple-Negative Breast Cancer.
Kaidun P; Holzmayer SJ; Greiner SM; Seller A; Tegeler CM; Hagelstein I; Mauermann J; Engler T; Koch A; Hartkopf AD; Salih HR; Märklin M
Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37685962
[TBL] [Abstract][Full Text] [Related]
36. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
[TBL] [Abstract][Full Text] [Related]
37. Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC.
Basher F; Jeng EK; Wong H; Wu J
Oncotarget; 2016 Jan; 7(1):814-30. PubMed ID: 26625316
[TBL] [Abstract][Full Text] [Related]
38. Novel NKG2D-directed bispecific antibodies enhance antibody-mediated killing of malignant B cells by NK cells and T cells.
Lutz S; Klausz K; Albici AM; Ebinger L; Sellmer L; Teipel H; Frenzel A; Langner A; Winterberg D; Krohn S; Hust M; Schirrmann T; Dübel S; Scherließ R; Humpe A; Gramatzki M; Kellner C; Peipp M
Front Immunol; 2023; 14():1227572. PubMed ID: 37965326
[TBL] [Abstract][Full Text] [Related]
39. A CS1-NKG2D Bispecific Antibody Collectively Activates Cytolytic Immune Cells against Multiple Myeloma.
Chan WK; Kang S; Youssef Y; Glankler EN; Barrett ER; Carter AM; Ahmed EH; Prasad A; Chen L; Zhang J; Benson DM; Caligiuri MA; Yu J
Cancer Immunol Res; 2018 Jul; 6(7):776-787. PubMed ID: 29769244
[TBL] [Abstract][Full Text] [Related]
40. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]